Cargando…

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway

Interferon beta (IFNβ) therapy has immunogenic properties and induces the development of neutralizing antibodies (NAbs). From the extensive literature focused in the development of NAbs in multiple sclerosis (MS) patients, their ability to cross-react has been deficiently evaluated, despite having i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurtado-Guerrero, Isaac, Pinto-Medel, Maria Jesus, Urbaneja, Patricia, Rodriguez-Bada, Jose Luis, Ortega-Pinazo, Jesús, Serrano, Pedro, Fernández, Óscar, Leyva, Laura, Oliver-Martos, Begoña
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707350/ https://www.ncbi.nlm.nih.gov/pubmed/29185487 http://dx.doi.org/10.1038/s41598-017-16828-x

Ejemplares similares

Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß
por: Hurtado-Guerrero, Isaac, et al.
Publicado: (2017)

Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
por: Pinto-Medel, María Jesús, et al.
Publicado: (2017)

Skin Phototype Could Be a Risk Factor for Multiple Sclerosis
por: Urbaneja, Patricia, et al.
Publicado: (2020)

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
por: López-Gómez, Carlos, et al.
Publicado: (2016)

Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients
por: López-Gómez, Carlos, et al.
Publicado: (2013)

Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
por: Aliaga-Gaspar, Pablo, et al.
Publicado: (2021)

Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation
por: Hurtado-Guerrero, Isaac, et al.
Publicado: (2020)

Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway
por: Au-Yeung, Nancy, et al.
Publicado: (2013)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

Small Molecule Inhibitors of Interferon‐Induced JAK‐STAT Signalling
por: Thoidingjam, Leishemba K., et al.
Publicado: (2022)

Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations
por: Ciano-Petersen, Nicolás Lundahl, et al.
Publicado: (2023)

Varicella Viruses Inhibit Interferon-Stimulated JAK-STAT Signaling through Multiple Mechanisms
por: Verweij, Marieke C., et al.
Publicado: (2015)

Spatiotemporal control of interferon-induced JAK/STAT signalling and gene transcription by the retromer complex
por: Chmiest, Daniela, et al.
Publicado: (2016)

Post-transcriptional regulatory feedback encodes JAK-STAT signal memory of interferon stimulation
por: Kalliara, Eirini, et al.
Publicado: (2022)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
por: Majoros, Andrea, et al.
Publicado: (2017)

A JAK/STAT invasion
por: Wells, William A.
Publicado: (2002)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

The Drosophila JAK-STAT pathway
por: Zeidler, Martin P, et al.
Publicado: (2013)

Evolution of the JAK-STAT pathway
por: Liongue, Clifford, et al.
Publicado: (2013)

The JAK-STAT pathway at 20
por: Darnell, Jr., James E.
Publicado: (2012)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

Eriobotrya japonica Water Extract Characterization: An Inducer of Interferon-Gamma Production Mainly by the JAK-STAT Pathway
por: Matalka, Khalid Z., et al.
Publicado: (2016)

Sandfly Fever Viruses Attenuate the Type I Interferon Response by Targeting the Phosphorylation of JAK-STAT Components
por: Moalem, Yarden, et al.
Publicado: (2022)

The role of the interferon/JAK-STAT axis in driving islet HLA-I hyperexpression in type 1 diabetes
por: Russell, Mark A., et al.
Publicado: (2023)

Porcine Respirovirus 1 Suppresses Host Type I Interferon Production and the JAK-STAT Signaling Pathway
por: Li, Yanhua, et al.
Publicado: (2023)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Interferon gamma runs interference on persistent COVID-19
por: Elliott, Eric Isaac, et al.
Publicado: (2021)

3C(pro) of FMDV inhibits type II interferon-stimulated JAK-STAT signaling pathway by blocking STAT1 nuclear translocation
por: Wu, Xiangju, et al.
Publicado: (2023)

JAK/STAT and Hox Dynamic Interactions in an Organogenetic Gene Cascade
por: Pinto, Pedro B., et al.
Publicado: (2015)

PD‐L1 expression is mainly regulated by interferon gamma associated with JAK‐STAT pathway in gastric cancer
por: Mimura, Kousaku, et al.
Publicado: (2017)

The Nucleoprotein and Phosphoprotein of Peste des Petits Ruminants Virus Inhibit Interferons Signaling by Blocking the JAK-STAT Pathway
por: Li, Pengfei, et al.
Publicado: (2019)

Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren’s Disease
por: Gupta, Sarthak, et al.
Publicado: (2023)

Coupled small molecules target RNA interference and JAK/STAT signaling to reduce Zika virus infection in Aedes aegypti
por: Trammell, Chasity E., et al.
Publicado: (2022)

Intranasal Administration of Interferon Beta Attenuates Neuronal Apoptosis via the JAK1/STAT3/BCL-2 Pathway in a Rat Model of Neonatal Hypoxic-Ischemic Encephalopathy
por: Dixon, Brandon J., et al.
Publicado: (2016)

BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant
por: Knabl, Ludwig, et al.
Publicado: (2022)

JAK-STAT in heterochromatin and genome stability
por: Silver-Morse, Louise, et al.
Publicado: (2013)

JAK-STAT and intestinal mucosal immunology
por: Heneghan, Aaron F, et al.
Publicado: (2013)

JAK-STAT: Getting to the heart of the matter
por: Barry, Sean P.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mamauohsm9f5qcivt6q7d3rdc1